Long Noncoding RNA ADAMTS9-AS2 Inhibits the Proliferation, Migration, and Invasion in Bladder Tumor Cells

Zhan Zhang1, Jin-Peng Jia2, Yin-Jiang Zhang3

  • 1Department of Rehabilitation Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433, People's Republic of China.

Oncotargets and Therapy
|August 18, 2020
PubMed
Abstract

Insights

The long noncoding RNA ADAMTS9-AS2 acts as a tumor suppressor in bladder cancer. It inhibits cell proliferation, migration, and invasion, potentially via the PI3K/AKT/mTOR pathway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Bladder cancer is a prevalent malignancy with incompletely understood pathogenesis.
  • Long noncoding RNAs (lncRNAs) are increasingly recognized for their roles in cancer, but many remain uncharacterized.
  • The lncRNA ADAMTS9-AS2 has been implicated in various cancers, but its function in bladder cancer was unexplored.

Purpose of the Study:

  • To investigate the role and potential mechanism of lncRNA ADAMTS9-AS2 in bladder tumor cells.
  • To determine if ADAMTS9-AS2 expression correlates with bladder tumor progression.
  • To explore ADAMTS9-AS2's impact on cell proliferation, migration, and invasion.

Main Methods:

  • Quantitative real-time PCR and bioinformatic analyses to assess ADAMTS9-AS2 and ADAMTS9 expression.
  • Western blot assays to evaluate protein levels of key molecules.
  • Cell proliferation (CCK8, clonogenic assays), migration (scratch wound healing), and invasion (Transwell assays) were performed.

Main Results:

  • ADAMTS9-AS2 was found to be downregulated in bladder tumor cells.
  • Overexpression of ADAMTS9-AS2 suppressed proliferation, migration, and invasion.
  • ADAMTS9-AS2 expression positively correlated with ADAMTS9 and was linked to the PI3K/AKT/mTOR pathway, autophagy, and apoptosis-related proteins.

Conclusions:

  • ADAMTS9-AS2 functions as a tumor suppressor in bladder cancer, inhibiting cell proliferation, migration, and invasion.
  • The mechanism involves regulation of the PI3K/AKT/mTOR pathway and key autophagy/apoptotic proteins.
  • ADAMTS9-AS2 shows potential as a diagnostic biomarker for bladder cancer patients.